REMEDY-PILOT: Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.

Sponsor

Imperial College London (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05492110

Collaborator

Bradford Teaching Hospitals NHS Foundation Trust (Other), East and North Hertfordshire NHS Trust (Other), Epsom and St Helier University Hospitals NHS Trust (Other), Guy's and St Thomas' NHS Foundation Trust (Other), Imperial College Healthcare NHS Trust (Other), Kingston Hospital NHS Trust (Other), London North West Healthcare NHS Trust (Other), Oxford University Hospitals NHS Trust (Other), Royal Brompton & Harefield NHS Foundation Trust (Other), St George's University Hospitals NHS Foundation Trust (Other), Liverpool University Hospitals NHS Foundation Trust (Other)

Enrollment

Location

Arms

Anticipated Duration (Months)

1.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To demonstrate the feasibility and efficacy of the CS Reducer for the treatment of patients with ischaemia and non-obstructed coronary arteries (INOCA) and coronary microvascular dysfunction (CMD) and through a nested mechanistic substudy investigate the physiological responses in the coronary microcirculation responsible for changes in myocardial perfusion.

Condition or Disease	Intervention/Treatment	Phase
Refractory Angina Microvascular Angina Microvascular Coronary Artery Disease Coronary Disease Angina Pectoris	Device: Coronary sinus reducer Other: Sham-procedure Diagnostic Test: Invasive coronary physiology	N/A

Detailed Description

Symptomatic angina in patients with ischaemia and non-obstructed coronary arteries (INOCA) is common and associated with increased morbidity and adverse outcomes. Myocardial ischaemia often arises from coronary microvascular dysfunction (CMD). Current treatments are limited, and novel evidence-based therapies are needed to address this large unmet clinical need. The Coronary Sinus Reducer (CS Reducer) is a new treatment for refractory angina, which creates a focal narrowing in the coronary sinus that increases back pressure and redistributes blood into ischaemic myocardium at the level of the microcirculation. However the precise mechanism remains unknown. This study will be a randomised double-blinded sham-controlled pilot study (REMEDY-PILOT) to confirm acceptability of CS Reducer implantation, demonstrate feasibility to recruit and quantify its effect on myocardial perfusion. A nested mechanistic substudy within REMEDY-PILOT will test the hypothesis that CS Reducer implantation alters measures of invasive coronary microcirculatory physiology as the mechanistic basis for observed changes in quantitative CMR stress perfusion, symptoms and quality of life.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

54 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Randomised, double-blinded, sham-controlled pilot study with parallel arms of participants randomised to CS Reducer or sham procedureRandomised, double-blinded, sham-controlled pilot study with parallel arms of participants randomised to CS Reducer or sham procedure

Masking:

Triple (Participant, Care Provider, Outcomes Assessor)

Masking Description:

Participants will be randomised and blinded to CS Reducer of sham procedure. All follow-up assessments will be performed by a blinded parallel team to ensure blinded outcomes analysis.

Primary Purpose:

Treatment

Official Title:

REducing Microvascular Dysfunction in Patients With Angina, Ischaemia and unobstructED coronarY Arteries - a PILOT Study

Anticipated Study Start Date :

Aug 6, 2022

Anticipated Primary Completion Date :

Apr 6, 2025

Anticipated Study Completion Date :

Aug 7, 2025

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: CS Reducer implantation	Device: Coronary sinus reducer The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina. Diagnostic Test: Invasive coronary physiology Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
Sham Comparator: Sham procedure	Other: Sham-procedure Implantation procedure with no device implanted Diagnostic Test: Invasive coronary physiology Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy

Arm

Intervention/Treatment

Active Comparator: CS Reducer implantation

Device: Coronary sinus reducer

The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.

Diagnostic Test: Invasive coronary physiology

Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy

Sham Comparator: Sham procedure

Other: Sham-procedure

Implantation procedure with no device implanted

Diagnostic Test: Invasive coronary physiology

Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy

Outcome Measures

Primary Outcome Measures

number of patients consenting to participate in the study. [6 months]
Consent rate
Premature withdrawal rate including reasons for withdrawal [6 months]
Registry of patients either failing screening or unwilling to consent to full trial
Change in myocardial perfusion [6 months]
Change at 6 months post randomisation, compared to baseline, in quantitative myocardial perfusion (global myocardial perfusion reserve [MPR]) assessed by cardiac MRI.

Secondary Outcome Measures

Canadian Cardiovascular Society (CCS) Angina Score [6 months]
Change in CCS class from baseline to 6 months post-randomisation. The CCS grading system for angina is a clinical tool used by doctors to assess the degree of severity of a patient's angina. Possible scores range from Class 0 (asymptomatic angina) to Class IV (angina at rest).
Seattle Angina Questionnaire (SAQ) score [6 months]
Change in SAQ score from baseline to 6 months. The Seattle Angina Questionnaire (SAQ) is a disease-specific questionnaire used to quantify patients' symptoms of angina and the extent to which their angina affects their functioning and quality of life. Possible scores range from 0 (daily angina) to 100 (no angina). Lower scores indicate worse angina symptoms.
Short-form 36 (SF-36) [6 months]
Change in SF-36 scores from baseline to 6 months. Validated questionnaire to assess quality of life. 36 items each scored from 0-100 with higher scores indicating a more favourable health state.
Hospital Anxiety and Depression Scale (HADS) [6 months]
Change in HADS score from baseline to 6 months. Scores range from 0 to 21. Normal results are indicated by lower scores. Validated questionnaire to assess psychological wellbeing.
6-minute walk test (6MWT) [6 months]
Change in exercise capacity from baseline to 6 months. Distance in metres walked in 6 minutes.
BORG scale of perceived exertion [6 months]
Change in BORG scale from baseline to 6 months. Scores range from 0 to 20 (BORG scale) or 0 to 10 (Modified BORG scale). The higher the self-reported score, the greater perceived exertion.
Safety events - rate of major adverse events [6 months]
The rate of occurrence of a composite of death, myocardial infarction (MI), pericardial effusion requiring surgical or percutaneous intervention, device embolisation, or BARC 3 or 5 bleeding evaluation in the CS Reducer arm compared to the sham-procedure arm.

Other Outcome Measures

Change in absolute global myocardial perfusion (ml/min/g) at rest and during adenosine stress (transmural, endocardial, epicardial) from baseline to 6 months post-randomisation [6 months]
Change in absolute myocardial perfusion (ml/min/g) at rest and during adenosine stress (transmural, endocardial, epicardial) from baseline to 6 months post-randomisation in the distribution territory of the left coronary circulation. [6 months]
Change in global endocardial:epicardial perfusion ratio at rest and after adenosine stress from baseline to 6 months post-randomisation [6 months]
Change in endocardial:epicardial perfusion ratio at rest and after adenosine stress from baseline to 6 months post-randomisation in the distribution territory of the left coronary circulation. [6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age >18 years
Ongoing symptomatic angina, CCS Class II-IV, for ≥3 months despite background treatment with at least two anti-anginal drug at the maximal tolerated dose.
Patients willing to consider no change in anti-anginal drug treatment for the duration of their participation in the trial.
Unobstructed coronary arteries with ≤30% epicardial stenoses demonstrated on coronary angiography.
Circumferential subendocardial stress-induced hypoperfusion on CMR (global MPR < 2.5).
Willingness to comply with the specified follow-up evaluation and to be contactable during the period of the trial.
Understands the nature of the trial procedures and provides written informed consent.

Exclusion Criteria:

Epicardial CAD (stenoses > 30%), previous percutaneous coronary intervention (PCI), coronary artery bypass grafting, or myocardial infarction (MI).
Abnormal coronary sinus anatomy (tortuosity, aberrant branch, persistent left superior vena cava)
Coronary sinus diameter at site of implant <9.5mm or >13mm
Mean right atrial pressure <15mmHg at time of implantation
Any structural heart disease including left ventricular hypertrophy; cardiomyopathy; severe valvular heart disease; previous valve replacement; myocardial bridge on angiography; LVEF<45% by CMR.
Clinically or angiographically diagnosed coronary vasospasm
Previous hospitalisation for decompensated heart failure
Pacemaker or defibrillator electrode in the right atrium, right ventricle or coronary sinus
Documented arrhythmia requiring planned implantation of a permanent pacemaker or defibrillator
Chronic kidney disease (creatinine >200 μmol/L; established on renal replacement therapy; functioning renal transplant)
Haemoglobin <80g/L
Contraindications to receiving dual anti-platelet therapy
Severe chronic obstructive pulmonary disease (FEV1 <55% predicted)
Moribund patients with life expectancy < 1year
Known allergy to nickel or steel
Current enrolment in another investigational device or drug trial
Contraindications to CMR or receiving intravenous adenosine
Pregnancy